MCID: BLD032
MIFTS: 42

Bile Duct Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Adenocarcinoma

MalaCards integrated aliases for Bile Duct Adenocarcinoma:

Name: Bile Duct Adenocarcinoma 12 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:4896
NCIt 51 C27813
SNOMED-CT 69 70179006
UMLS 74 C1370800

Summaries for Bile Duct Adenocarcinoma

Disease Ontology : 12 A bile duct carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bile Duct Adenocarcinoma is related to adenocarcinoma and gastrointestinal stromal tumor. An important gene associated with Bile Duct Adenocarcinoma is PRRT2 (Proline Rich Transmembrane Protein 2), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Trioxsalen and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and breast, and related phenotypes are Decreased viability in esophageal squamous lineage and Reduced mammosphere formation

Related Diseases for Bile Duct Adenocarcinoma

Diseases related to Bile Duct Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.5 AKT1 CDH1 EPCAM HRAS KRAS MUC1
2 gastrointestinal stromal tumor 30.1 AKT1 KRAS S100A1 TP53
3 extrahepatic bile duct adenocarcinoma 12.6
4 papillary extrahepatic bile duct adenocarcinoma 12.3
5 episodic kinesigenic dyskinesia 2 10.5 HRAS PRRT2
6 malignant ectomesenchymoma 10.5 HRAS S100A1
7 vulvar intraepithelial neoplasia 10.5 KRT7 TP53
8 papillary tumor of the pineal region 10.5 MUC1 S100A1
9 cerebellar astrocytoma 10.5 IDH1 TP53
10 endosalpingiosis 10.5 KRT7 MUC1
11 periampullary adenoma 10.5 HRAS KRAS
12 paronychia 10.5 HRAS KRAS
13 hyperplastic polyposis syndrome 10.5 KRAS TP53
14 adult oligodendroglioma 10.5 IDH1 IDH2
15 enchondroma 10.5 IDH1 IDH2
16 large intestine adenocarcinoma 10.5 CDH1 KRT7
17 linitis plastica 10.5 CDH1 KRT7
18 protoplasmic astrocytoma 10.5 IDH2 TP53
19 sinonasal undifferentiated carcinoma 10.5 IDH2 MUC1
20 cerebral convexity meningioma 10.5 CDH1 TP53
21 proliferating trichilemmal cyst 10.5 KRT19 KRT7
22 hepatoblastoma 10.4 AFP KRT7 TP53
23 mucinous adenofibroma 10.4 CEACAM5 KRT7
24 cutaneous mucoepidermoid carcinoma 10.4 CEACAM5 KRT7
25 melanotic medulloblastoma 10.4 AFP CEACAM5
26 renal cell carcinoma, papillary, 1 10.4 HRAS KRT7 TP53
27 malignant peripheral nerve sheath tumor 10.4 MUC1 S100A1 TP53
28 testicular germ cell tumor 10.4 AFP HRAS TP53
29 thymus cancer 10.4 KRT7 MUC1 TP53
30 leukemia, chronic lymphocytic 2 10.4 HRAS KRAS TP53
31 differentiated thyroid carcinoma 10.4 HRAS KRAS TP53
32 interval angle-closure glaucoma 10.4 IDH1 IDH2
33 teratoma 10.4 AFP KRT7 TP53
34 gonadal disease 10.4 AFP AKT1 TP53
35 spiradenoma 10.4 KRT7 MUC1 TP53
36 appendix disease 10.3 HRAS KRAS KRT7
37 esophageal adenosquamous carcinoma 10.3 CDH1 CEACAM5
38 mature teratoma 10.3 AFP KRAS TP53
39 uterine carcinosarcoma 10.3 CDH1 HRAS TP53
40 sertoli-leydig cell tumor 10.3 AFP KRT7 MUC1
41 cystadenofibroma 10.3 AFP KRT7 MUC1
42 acinar cell carcinoma 10.3 AFP KRT7 TP53
43 ovarian serous cystadenocarcinoma 10.3 AKT1 HRAS TP53
44 epithelial-myoepithelial carcinoma 10.3 HRAS KRT7 TP53
45 glioma susceptibility 1 10.3 IDH1 IDH2 TP53
46 cecum adenocarcinoma 10.3 HRAS KRAS KRT7
47 fibrillary astrocytoma 10.3 IDH1 IDH2 TP53
48 appendix cancer 10.3 KRT7 MUC1 TP53
49 intrahepatic bile duct adenoma 10.3 AFP KRT19 KRT7
50 germ cell and embryonal cancer 10.3 AFP KRT7 TP53

Graphical network of the top 20 diseases related to Bile Duct Adenocarcinoma:



Diseases related to Bile Duct Adenocarcinoma

Symptoms & Phenotypes for Bile Duct Adenocarcinoma

GenomeRNAi Phenotypes related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.65 AFP CDH1 HRAS IDH1 IDH2 KRAS
2 Reduced mammosphere formation GR00396-S 9.17 AFP CDH1 HRAS IDH2 KRAS KRT7

MGI Mouse Phenotypes related to Bile Duct Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.73 AFP AKT1 CDH1 EPCAM HRAS IDH1
2 neoplasm MP:0002006 9.28 AFP AKT1 CDH1 HRAS IDH2 KRAS

Drugs & Therapeutics for Bile Duct Adenocarcinoma

Drugs for Bile Duct Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 3 3902-71-4 5585
2
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4 Ether Phase 3
5 Dermatologic Agents Phase 3
6
s 1 (combination) Phase 3,Not Applicable
7 Dihematoporphyrin Ether Phase 3
8 Photosensitizing Agents Phase 3
9 Hematoporphyrin Derivative Phase 3
10 Antimetabolites, Antineoplastic Phase 3,Phase 1
11 Antimetabolites Phase 3,Phase 1
12 Immunologic Factors Phase 3,Phase 1
13 Immunosuppressive Agents Phase 3
14 Antiviral Agents Phase 3
15 Anti-Infective Agents Phase 3
16 Hematoporphyrins Phase 3
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18 Protein Kinase Inhibitors Phase 2
19
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
20
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
21
Durvalumab Approved, Investigational Phase 1 1428935-60-7
22 Guadecitabine Investigational Phase 1 929901-49-5
23 Antibodies Phase 1
24 Liver Extracts Phase 1
25 Antibodies, Monoclonal Phase 1
26 Antineoplastic Agents, Immunological Phase 1
27 Immunoglobulins Phase 1
28
Bilirubin Not Applicable 635-65-4, 69853-43-6 21252250 5280352

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
2 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
3 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
4 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine
5 Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery Withdrawn NCT03117855 Phase 1 Capecitabine
6 Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma Active, not recruiting NCT02592538 Not Applicable S-1

Search NIH Clinical Center for Bile Duct Adenocarcinoma

Genetic Tests for Bile Duct Adenocarcinoma

Anatomical Context for Bile Duct Adenocarcinoma

MalaCards organs/tissues related to Bile Duct Adenocarcinoma:

42
Liver, Lung, Breast, Bone, Pancreas, Ovary, Appendix

Publications for Bile Duct Adenocarcinoma

Articles related to Bile Duct Adenocarcinoma:

(show all 18)
# Title Authors Year
1
An extremely rare case of distal common bile duct adenocarcinoma in a 65-year-old male patient. ( 29940641 )
2018
2
Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty. ( 29279503 )
2018
3
Intraductal papillary bile duct adenocarcinoma and gastrointestinal stromal tumor in a case of neurofibromatosis type 1. ( 29398874 )
2018
4
Bile Duct Adenocarcinoma with Acute on Chronic Pancreatitis: A Rare Complication of Long Standing Choledochal Cyst. ( 28764249 )
2017
5
Laryngeal metastasis from bile duct adenocarcinoma. ( 26614301 )
2016
6
Differentiation grade for extrahepatic bile duct adenocarcinoma: Assessed by diffusion-weighted imaging at 3.0-T MR. ( 27776649 )
2016
7
Prognostic Value of FDG-PET/CT Total Lesion Glycolysis for Patients with Resectable Distal Bile Duct Adenocarcinoma. ( 26637926 )
2015
8
Common bile duct adenocarcinoma in a patient with situs inversus totalis: report of a rare case. ( 23234596 )
2012
9
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. ( 20224368 )
2010
10
Bile duct adenocarcinoma with minor micropapillary component: a case report. ( 19144165 )
2009
11
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. ( 18754070 )
2008
12
Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. ( 15191867 )
2004
13
Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. ( 14585411 )
2003
14
The role of S100A4 gene encoding an S100-related calcium-binding protein in human bile duct adenocarcinoma cell lines: correlation of S100A4 expression and invasive growth in Matrigel Matrix. ( 11029520 )
2000
15
Bile duct adenocarcinoma mimicking veno-occlusive disease after autologous bone marrow transplantation for acute leukaemia. ( 9674864 )
1998
16
Bile duct adenocarcinoma in a pallid bat (Antrozeous pallidus). ( 6290689 )
1982
17
Bile duct adenocarcinoma with Leser-Trelat sign and pure red blood cell aplasia. ( 6448089 )
1980
18
CLINICOPATHOLOGICAL reports; intrahepatic bile duct adenocarcinoma. ( 14836459 )
1951

Variations for Bile Duct Adenocarcinoma

Expression for Bile Duct Adenocarcinoma

Search GEO for disease gene expression data for Bile Duct Adenocarcinoma.

Pathways for Bile Duct Adenocarcinoma

Pathways related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 AKT1 CDH1 HRAS KRAS TP53
2 12.79 AKT1 CDH1 HRAS KRAS TP53
3
Show member pathways
12.72 AKT1 CDH1 HRAS KRAS TP53
4
Show member pathways
12.66 AKT1 CDH1 HRAS KRAS TP53
5
Show member pathways
12.65 AKT1 CDH1 HRAS KRAS TP53
6 12.42 CDH1 EPCAM KRT19 KRT7 MUC1
7
Show member pathways
12.4 AKT1 HRAS KRAS TP53
8
Show member pathways
12.39 HRAS KRAS MUC1 MUC5AC
9 12.31 AKT1 HRAS KRAS TP53
10 12.24 AKT1 HRAS KRAS TP53
11
Show member pathways
12.2 AKT1 HRAS KRAS TP53
12
Show member pathways
12.17 CEACAM5 EPCAM HRAS KRAS
13
Show member pathways
12.16 AKT1 HRAS KRAS TP53
14 12.12 AKT1 CDH1 KRAS TP53
15 12.1 AKT1 HRAS KRAS TP53
16
Show member pathways
12.1 AKT1 HRAS KRAS TP53
17 12.07 AKT1 HRAS KRAS TP53
18 12.07 AKT1 CDH1 KRAS TP53
19
Show member pathways
12.06 AKT1 HRAS KRAS TP53
20
Show member pathways
12.05 AKT1 HRAS KRAS TP53
21 11.99 AKT1 CDH1 HRAS KRAS
22
Show member pathways
11.96 AKT1 HRAS KRAS TP53
23
Show member pathways
11.92 AKT1 CDH1 HRAS KRAS MUC1 TP53
24 11.9 CDH1 CEACAM5 EPCAM MUC1
25 11.89 AKT1 CDH1 HRAS KRAS
26 11.85 AKT1 HRAS KRAS TP53
27 11.8 AKT1 HRAS KRAS TP53
28 11.77 AKT1 HRAS KRAS TP53
29 11.75 AFP AKT1 TP53
30
Show member pathways
11.75 AKT1 HRAS KRAS
31 11.64 AKT1 HRAS TP53
32 11.63 HRAS KRAS TP53
33 11.6 AKT1 HRAS KRAS TP53
34 11.53 AKT1 HRAS KRAS TP53
35 11.32 CDH1 HRAS KRAS TP53
36 11.28 HRAS KRAS TP53
37 11.23 AKT1 HRAS KRAS
38 11.12 AKT1 CDH1 HRAS
39 11.02 AKT1 HRAS KRAS
40 10.97 AKT1 HRAS KRAS
41 10.83 AKT1 HRAS IDH1 KRAS TP53
42
Show member pathways
10.8 IDH1 IDH2
43 10.8 HRAS KRAS

GO Terms for Bile Duct Adenocarcinoma

Cellular components related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.32 CDH1 CEACAM5 EPCAM IDH1 IDH2 KRT19

Biological processes related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.54 HRAS KRAS TP53
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 MUC1 TP53
3 NADP metabolic process GO:0006739 9.4 IDH1 IDH2
4 response to isolation stress GO:0035900 9.32 HRAS KRAS
5 isocitrate metabolic process GO:0006102 9.26 IDH1 IDH2
6 glyoxylate cycle GO:0006097 9.16 IDH1 IDH2
7 positive regulation of nitric-oxide synthase activity GO:0051000 9.13 AKT1 KRAS S100A1
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 HRAS KRAS MUC1 MUC5AC

Molecular functions related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.73 AKT1 CDH1 CEACAM5 IDH1 IDH2 S100A1
2 identical protein binding GO:0042802 9.23 AKT1 CDH1 CEACAM5 IDH1 PPFIBP2 S100A1
3 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH1 IDH2
4 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2

Sources for Bile Duct Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....